Up to 70% of individuals receiving subcutaneous apomorphine can develop skin nodules,8 although this adverse event does not usually lead to discontinuation.9 Practical options can reduce the risk of nodules, including good skin hygiene and rotation of needles, and ultrasound can reduce pain. Grants and contract support to SHF include funding from the Michael J Fox Foundation for Parkinson Research and the Edmond J Safra Foundation, the National Institutes of Health (US; Dystonia Coalition), Parkinson Canada, and the Parkinson Foundation (US). SHF reports honoraria for lectures paid to the institution from the International Parkinson and Movement Disorder Society, BIAL pharmaceutical company, and Lundbeck, consulting fees from Ipsen Pharmaceutical and Sunovion Pharmaceuticals; and SHF received royalties from Oxford University Press.